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Abstract
Copy number variants (CNVs) at chromosome 16p13.11 have been associated with a range of neurodevelopmental
disorders including autism, ADHD, intellectual disability and schizophrenia. Significant sex differences in prevalence, course
and severity have been described for a number of these conditions but the biological and environmental factors underlying
such sex-specific features remain unclear. We tested the burden and the possible sex-biased effect of CNVs at 16p13.11 in a
sample of 10,397 individuals with a range of neurodevelopmental conditions, clinically referred for array comparative
genomic hybridisation (aCGH); cases were compared with 11,277 controls. In order to identify candidate phenotype-
associated genes, we performed an interval-based analysis and investigated the presence of ohnologs at 16p13.11; finally,
we searched the DECIPHER database for previously identified 16p13.11 copy number variants. In the clinical referral series,
we identified 46 cases with CNVs of variable size at 16p13.11, including 28 duplications and 18 deletions. Patients were
referred for various phenotypes, including developmental delay, autism, speech delay, learning difficulties, behavioural
problems, epilepsy, microcephaly and physical dysmorphisms. CNVs at 16p13.11 were also present in 17 controls.
Association analysis revealed an excess of CNVs in cases compared with controls (OR= 2.59; p = 0.0005), and a sex-biased
effect, with a significant enrichment of CNVs only in the male subgroup of cases (OR= 5.62; p = 0.0002), but not in females
(OR= 1.19, p = 0.673). The same pattern of results was also observed in the DECIPHER sample. Interval-based analysis
showed a significant enrichment of case CNVs containing interval II (OR = 2.59; p = 0.0005), located in the 0.83 Mb genomic
region between 15.49–16.32 Mb, and encompassing the four ohnologs NDE1, MYH11, ABCC1 and ABCC6. Our data confirm
that duplications and deletions at 16p13.11 represent incompletely penetrant pathogenic mutations that predispose to a
range of neurodevelopmental disorders, and suggest a sex-limited effect on the penetrance of the pathological phenotypes
at the 16p13.11 locus.
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Introduction
Copy number variants (CNVs) represent one the most prevalent
types of structural variations detected in the human genome and
are a major source of human genetic variability [1–4]. Many rare
CNVs are associated with pathological conditions, including
classic ‘‘genomic disorders’’, such Williams-Beuren syndrome
(deletion at 7q11.23; OMIM 194050), as well as those with a
complex genetic aetiology such as schizophrenia and autism
spectrum disorders [5–8]. Many of these complex disorders show a
distorted sex ratio, usually with an excess of affected males. In
autism spectrum disorders the male: female ratio is usually quoted
at about 4:1, but may be higher [9], and a significant male excess
is also found in schizophrenia, albeit less pronounced at about
1.4:1 [10]. The reasons for this are unknown, but appear to be
largely autosomal in origin and could result from a variety of
factors, including imprinting, endocrine or neurodevelopmental
factors, which result in a categorical protection from expression in
females (resilience) [11]. A better understanding might provide
insight for the development of treatments. The identification and
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characterisation of specific autosomal loci showing sex-biased
effects will be an important step in this direction.
Putatively pathogenic CNVs may arise de novo or be inherited,
and many show a pleiotropic effect, with broad phenotypic
manifestations and incomplete penetrance both overall and for
specific disorders [12]. An important genomic ‘‘hotspot’’ for these
variants is the 16p13.11 locus, which is especially rich in low-copy
repeats (LCRs). These highly homologous DNA sequences are
characteristically involved in non-allelic homologous recombina-
tion (NAHR), a major source of de novo genomic rearrangements in
human [13,14]. Deletions and reciprocal duplications at the
16p13.11 locus have been associated with disorders involving
neurodevelopment, including conditions such as autism, mental
retardation, schizophrenia and epilepsies, which appear to share
overlapping genetic aetiologies [15–25]. Pathogenic genomic
variants at 16p13.11 were initially described by Ullmann et al.
[15], who identified a 1.5 Mb duplication (14.89–16.39 Mb) and a
reciprocal deletion spanning the same interval, in four severe
autistic patients from three unrelated families, and in three
unrelated intellectually disabled patients. In the affected subjects,
some of the imbalances were inherited from unaffected or mildly
affected parents, indicating incomplete penetrance [15]. In a
subsequent study, Hannes et al. identified six deletions and seven
duplications at the 16p13.11 locus in thirteen unrelated patients
affected by intellectual disability and/or multiple congenital
anomalies; five deletions and five duplications spanned approxi-
mately the same 1.5 Mb region identified in the first report, whilst
the other three patients carried atypical larger rearrangements,
including two duplications of ,3.4 Mb in size (15.1–18.5 Mb),
overlapping the typical 1.5 Mb region, and a deletion of ,1.6–
2.1 Mb (16.3–18.4 Mb), flanking the region. Of the variations
identified, one duplication occurred de novo, two deletions and two
duplications were inherited from an apparently unaffected parent,
and one duplication was inherited from a mildly affected mother
[16].
CNVs at 16p13.11 identical or similar to the variants originally
described have subsequently been identified in several cohorts of
patients affected by schizophrenia, epilepsies, attention-deficit
hyperactivity disorder (ADHD), developmental delay (DD),
dysmorphic features and multiple congenital anomalies and, most
recently, thoracic aortic aneurysms and dissections (TAAD) [15–
25]. Significant sex differences in prevalence, course and severity
have been described for a number of these conditions but the
biological and environmental factors underlying these sex-specific
features remain unclear. Among the possible biological factors, an
important role is thought to be played by sex-hormone levels,
which differ between males and females, and are particularly
relevant during fetal and neonatal development, acting on the
brain to produce sex differences in behaviour, cognition, brain
structure and function [26].
Genetic factors are likely to represent another major determi-
nant of phenotypic dimorphism [27]. A sex-specific genetic
architecture has been observed for a variety of quantitative and
disease-related traits and recent studies suggest that, together with
the well established contribution of the genes on the sex
chromosomes, natural variation within the autosomal genome
also plays an important role in the aetiology of these sexually
dimorphic features; in this context, sex could be considered as an
environmental factor that interacts with the autosomal genes and
modulates penetrance and expressivity of a number of traits [28].
Furthermore, the sex-specific autosomal effects are likely to be in
part explained by factors that are not directly associated with
nucleotide sequence changes and that operate at the interface
between the genome and the environment, such as differences in
gene-expression or epigenetic processes; these factors underlie
important phenotypic differences between the sexes, and have
therefore the potential, if perturbed, to convert such differences in
sex-specific susceptibility to disease [27,29].
In the present study, we investigated the burden and the
possible sex-biased effect of CNVs in the 16p13.11 region in a UK
sample of 10,397 children and young adults with a childhood onset
neurodevelopmental condition, referred for clinical genetic testing
by array comparative genomic hybridisation (aCGH), using a
60 K Agilent oligonucleotide platform.
Materials and Methods
Ethics Statement
The BBGRE project was approved by the Cambridgeshire
Central Research Ethics Committee. Under common UK law all
research using identifiable personal data requires the express
consent of the individuals involved. The use of non-identifiable
information does not fall under common law, i.e. informed
consent is not necessary for research using this type of data, when
it is irreversibly anonymised. This is specified in the UK Data
Protection Act (DPA) (1998), which came into force in 2000, in an
exemption clause for research using unlinked anonymised data:
‘‘Informed consent is not necessary for research which makes use
of unlinked anonymised data’’. Since the present study uses only
unlinked anonymised data, their use was therefore in accordance
with the UK Data Protection Act (DPA) (1998). See http://www.
legislation.gov.uk/ukpga/1998/29/contents for further informa-
tion.
Clinical Diagnostic Referral Cases
The clinical cytogenetic sample consisted of patients referred to
Guy’s and St Thomas NHS Foundation Trust from regional
paediatricians and other health specialists, as well as from genetics
centres both in and outside the region (South-East Thames). Array
CGH analysis was performed to determine if there were detectable
structural genetic abnormalities that could be of aetiological
significance for a range of problems including developmental delay
(DD), intellectual disability (ID), autism spectrum disorders (ASD),
attention-deficit hyperactivity disorder (ADHD), specific develop-
mental delays such as speech or language delay, birth defects or to
confirm a clinical diagnosis of a suspected syndrome. All patient
tests were carried out as part of standard clinical care, either as
clinical referrals for array CGH testing following a normal
karyotype, or those having array CGH as a first-line test in place
of karyotyping. All data were anonymised.
Array CGH Analysis
Testing was carried out at a cytogenetics CPA accredited
laboratory. DNA samples were analyzed by array comparative
genomic hybridisation (aCGH), using a 60 K Agilent array
(designs 028469 and 017457), with a total imbalance detection
rate of 24%. Array CGH analysis was performed as described
previously [30]. In brief, DNA extracted from blood samples
(1 mg) was labelled using CGH Labelling Kit for Oligo Arrays
(Enzo Life Sciences, USA), then applied to a 60 K oligonucleotide
array (Agilent, USA). Image quantification, array quality control
and aberration detection were performed using Feature Extraction
and DNA Analytics software packages (Agilent, USA) for oligo
arrays, according to the manufacturer’s instructions. All copy
number variations in the 16p13.11 region (46/46) were confirmed
either by a second CGH array with a different comparison sample
or by a multiplex ligation-dependent probe amplification assay
(MLPA kits P064, P245 and custom probes; MRC-Holland,
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Netherlands) [30,31]. Genomic data and referral phenotype
information was recorded in a clinical database, which at the
time of analysis contained 10,397 clinical referrals (63.4% males;
October 2012), including approximately 1,400 patients referred
for ASD, 26% of whom were female. The overall ethnic
distribution (self-reported data) was 70% Caucasians, 15%
Africans and 15% other/mixed ancestry. Copy number variants
in this population are available in the Brain and Body Genetic
Resource Exchange database (BB-GRE; http://bbgre.org).
Controls
We analysed a total sample of 6,078 control individuals,
including 459 controls (281 female, 178 male) comprehensively
screened for a lifetime absence of psychiatric disorder and 5,619
controls (2,611 female, 2,668 male) from the Wellcome Trust
Case-Control Consortium Phase II (WTCCC2). Screened controls
were recruited from students and staff at King’s College London;
subjects were interviewed with a modified version of the Past
History Schedule [32] and with the Beck Depression Inventory
[33] and were included only if they demonstrated no evidence of
past or present psychiatric disorder. The WTCCC2 control cohort
consists of the UK 1958 British birth cohort (58 BC) and a cohort
derived from the UK national blood service (NBS) [34]. Both
cohorts represent population control samples. DNA samples were
derived from immortalised cell lines (58 BC cohort) and venous
blood (screened controls and NBS cohort). Screened control
samples were genotyped on the Illumina HumanHap 610-Quad
beadchip, whereas WTCCC2 samples were genotyped on a
modified Illumina 1 M beadchip. To ensure comparable CNV
detection from different array types, control CNVs were identified
using a consensus marker set between the 610 K and 1 M chips,
which mimics the Illumina HumanHap 550 beadchip (detailed
description of data analysis and quality control criteria can be
found in the Methods S1 and in Rucker et al. [34]).
Additionally, we used control data from two previously
published studies by Shaikh et al. and Cooper et al. [35,36].
The Shaikh control sample consists of 2,026 healthy children
(1,104 female, 922 male) recruited within the Children’s Hospital
of Philadelphia (CHOP) health care network, uniformly genotyped
using the Illumina HumanHap 550 beadchip, with DNA samples
obtained from whole blood, (overall precision .96% in identifying
CNVs represented by .10 probes) (http://cnv.chop.edu) [35].
The Cooper control sample originally consisted of 8,329
individuals, but we used genomic information only for the subset
of 3,173 subjects (2,148 female, 1,025 male) for which gender data
were available. DNA was obtained from cell lines (HGDP,
n = 984), and blood samples (London, n = 760; FHCRC,
n = 1,429), and genotyping was performed using the Illumina
HumanHap 550 K, 650 Y and 610-Quad beadchips, with an
overall precision .89% in identifying CNVs .100 kbp (dbVar,
nstd54) [36].
Ethnic distribution in the total control population (n = 11,277)
was 77% Caucasians, 8.5% Africans and 14.5% other/mixed
ancestry. Although the control sample was slightly enriched in
Caucasians (77% vs 70%) and had slightly fewer African
individuals (8.5% vs 15%) compared to the case sample, we
found no significant differences in the frequency of
16p13.11 CNVs in the Caucasian and African control subgroups
(OR = 1.78; p = 1.0), which suggests no potential population
stratification problems.
Despite 33% of DNA samples in our control population were
derived from immortalized cell lines (58 BC and HGDP cohorts),
the CNV QC measures used in both the WTCCC2 and Cooper
et al. control cohorts were designed to account for potential cell
line mosaicism and artefacts (Methods S1) [34,36,37]. Moreover,
in order to further test for DNA source effects, we also split the
total control sample and compared the frequency of samples with
16p13.11 CNVs in the whole blood (0.14%) and cell line (0.20%)
subgroups, but we found no significant differences (OR = 1.39;
p = 0.498), which suggests that cell-line artefacts are not a major
contributor to our estimates of CNV burden.
Association Analysis
Pearson’s chi-square test or Fisher’s exact test, as appropriate,
were used to compare frequencies of NAHR-mediated CNVs in
cases and controls and to compare interval copy number
frequencies in case and control CNVs. All data analysis was
performed using the R language and environment for statistical
computing (http://www.r-project.org/).
Despite the platform heterogeneity in CNV detection, numer-
ous studies have shown that, whereas for small variations the CNV
detection power is dependent on the array used [38], different
array platforms have comparable sensitivity and specificity for the
detection of large CNVs (.500 kbp in size), and ten probes are
typically sufficient to detect such events [37,39,40]. Since the
16p13.11 duplications and deletions are large NAHR-mediated
variations with size .800 kbp, and given that the different array
platforms used for their detection in cases and controls have an
adequate probe coverage for the 16p13.11 region (Methods S1),
platform-specific differences in detection are unlikely to represent
a major confounding factor in our analyses.
DECIPHER Database Search
We performed a search in the DECIPHER database (https://
decipher.sanger.ac.uk), in order to identify additional cases with
CNVs in the 16p13.11 region. DECIPHER (Database of
Chromosomal Imbalance and Phenotype in Humans Using
Ensembl Resources) is an interactive web-based database that
collects clinical phenotype information and copy number change
data from a sample of .18,000 patients suffering from
developmental disorders, enabling clinical scientists worldwide to
maintain records for their patients and to share this information
with the clinical research community [41]. At the time of analysis
(October 2012), the DECIPHER database contained 18,451
clinical referrals, 54% of whom were male.
Evolutionary Genetic Analysis
Ohnologs in the 16p13.11 region were defined as described by
Makino and McLysaght [42]. Ohnologs were syntenic genes
located on paralogous chromosomal regions and derived from
whole genome duplication (WGD). A list of ohnologs in the region
was provided for the maximal CNV interval described in the
present study (Chr16:14.66–18.70 Mb, GRCh37/hg19), blind to
the coordinates of individual CNVs and to interval-based analyses
(Makino and McLysaght, personal communication).
Results
In the case series of 10,397 individuals, we identified 46 patients
with copy number variants of variable size at the 16p13.11 locus,
including 28 duplications (all NAHR-mediated) and 18 deletions
(16 NAHR-mediated and 2 non-NAHR mediated), all contained
within the region between 14.66 and 18.70 Mb (Human Genome
Build 37), where the previously reported copy number variants
have been described [15–25].
Given the high number of variable sized CNVs, for their
classification we referred to the study by Ingason et al. [19], who
subdivided the 16p13.11 region into three single copy sequence
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intervals called interval I, II and III, each flanked by sequences
rich in low copy repeats (LCRs). We identified seven distinct
categories of NAHR-mediated CNVs in the region, including nine
deletions and sixteen reciprocal duplications of intervals I and II,
one deletion and one duplication of intervals I, II and III, one
duplication of interval II, six deletions and ten duplications of
intervals II and III (Figure 1, Table 1, Table S1); furthermore, we
identified two cases carrying identical, non-NAHR mediated
23 kbp microdeletions encompassing the NTAN1 gene, and these
were excluded from the analyses (Figure S1, Table S1).
Within our two control groups, 348 screened controls and 4,828
unscreened controls passed quality control criteria and were thus
included in the analysis. We did not detect any 16p13.11 copy
number variation in the screened controls, whereas we identified
twelve NAHR-mediated CNVs in the WTCCC2 control groups,
including three deletions and nine duplications; additionally, three
NAHR-mediated duplications were identified in the Shaikh
controls, while one deletion and one duplication were identified
in the Cooper control group, with a total control CNV count of
17 CNVs and four distinct CNV categories (Figure 1, Table 1,
Table S2).
Association analysis showed a significant enrichment of NAHR-
mediated CNVs in cases compared with controls (OR = 2.59;
p = 0.0005), with the effect coming mostly from deletions
(OR = 4.00; p = 0.007), that were present in 0.15% of cases versus
0.04% of controls; duplications were also more common in the
cases, being identified in 0.27% of cases versus 0.12% of controls
(OR = 2.15; p = 0.019) (Table 2). Interestingly, performing a post
hoc sex-specific analysis, we observed a significant enrichment of
CNVs (OR = 5.62; p = 0.0002), coming from duplications
(OR = 3.40; p = 0.018) and, particularly, from deletions (OR =‘;
p = 0.001), only in the male subgroup of cases, but not in females
(All CNVs: OR = 1.19, p = 0.673; Del: OR = 1.16, p = 1.00; Dupl:
OR = 1.21, p = 0.708), in line with our preliminary hypothesis of a
possible sex-biased effect for the 16p13.11 CNVs. Finally, since
some of the cases with a 16p13.11 CNV also harboured a second
potentially pathogenic chromosomal imbalance, we performed a
post hoc analysis, excluding cases (7/44) and controls (3/17)
carrying additional very rare second-hit CNVs .500 kpb in size
(comparable sensitivity and specificity between aCGH and SNP
arrays) (Table S1, Table S2). This additional analysis confirmed all
the results described above, both overall (OR = 2.64; p = 0.0013),
and in the male (OR = 6.35; p = 0.00048) and female subgroups
(OR = 1.13; p = 0.794).
In an attempt to further confirm our findings, we next tested for
a sex-biased prevalence of the variations also in the DECIPHER
sample. The DECIPHER database search identified 101 patients
with NAHR-mediated CNVs at the 16p13.11 locus, including 61
duplications and 40 deletions, with nine distinct CNV categories
(Figure S2, Table S3, Table S4). Overall, we observed a significant
enrichment of CNVs in the cases compared with controls
(OR = 3.35; p = 9.861027), with the effect coming from both
deletions (OR = 5.63; p = 0.0002) and duplications (OR = 2.64;
p = 0.0009). Sex-specific analysis confirmed a significant overrep-
resentation of deletions (OR =‘; p = 0.0003) and duplications
(OR = 3.60; p = 0.0098) only in the male subgroup of cases but not
in females (Dupl: OR = 2.09, p = 0.051; Del: OR = 1.91, p = 0.26).
All the results were confirmed when we excluded from the analysis
cases (18/101) and controls (3/17) harbouring additional rare
second-hit CNVs .500 kpb in size (Overall: OR = 3.34,
p = 9.461026; Males: OR = 7.97, p = 3.261025; Females:
OR = 1.84, p = 0.082).
Given the very variable size of the genomic variations identified,
we next decided to perform a post hoc interval-based analysis,
comparing the frequencies of the three single copy sequence
intervals contained in our region of interest in case and control
CNVs, in order to identify a possible core pathogenic region,
harbouring the dosage-sensitive genes responsible for the delete-
rious phenotypes observed in our cases.
Interval-based analysis revealed a significant enrichment of case
CNVs containing interval II (OR = 2.59; p = 0.0005), which is
located in the 0.83 Mb genomic region between 15.49 and
16.32 Mb (Human Genome Build 37) and encompasses a core set
of 9 genes (MPV17L, C16orf45, KIAA0430, NDE1, MIR484,
MYH11, C16orf63, ABCC1, ABCC6); the interval II overrepre-
sentation was observed for both case deletions (OR = 4.00;
p = 0.007) and duplications (OR = 2.15; p = 0.019). In line with
the sex-specific analysis results described above, performing the
analysis in the male and female subgroups, we found a significant
enrichment of CNVs containing interval II (OR = 5.62;
p = 0.0002), coming from both deletions (OR =‘; p = 0.001) and
duplications (OR = 3.40; p = 0.018), only in the male subgroup of
cases, but not in females (OR = 1.19; p = 0.673). The same pattern
of results was also observed in the DECIPHER sample, both
overall (Dupl: OR = 2.60, p = 0.001; Del: OR = 5.49, p = 0.0003)
and in the two subgroups (Male: Dupl: OR = 3.60, p = 0.0098;
Del: OR =‘, p = 0.0004. Female: Dupl: OR = 2.01, p = 0.066;
Del: OR = 1.91, p = 0.26).
Finally, we applied an evolutionary genetic approach, and tried
to identify the disease-causing genes in the 16p13.11 region
through the mapping of ohnologs, genes retained after ancestral
whole genome duplication events, that are inferred to be
particularly enriched in dosage-sensitive genes [42]. We identified
a total of five ohnologs in the region, including NDE1, MYH11,
ABCC1, ABCC6 and XYLT1 (Figure 1, Table 3); interestingly,
four of the ohnologs (NDE1, MYH11, ABCC1, ABCC6) were
part of the core set of genes located in interval II, most
overrepresented in our case CNVs and are thus likely to represent
dosage-balanced ohnologs, involved in the aetiology of the
pathological phenotypes associated with the 16p13.11 copy
number variants.
16p13.11 CNVs in Neurodevelopmental Disorders
Phenotypic information was available for 41 of the 46 patients
with a copy number variation at 16p13.11, identified in the clinical
referral series (Table S1). Of them, the only patient not diagnosed
with a neurodevelopmental condition was a ten months old male
carrying a deletion of intervals II and III, who was referred for
testing as part of developmental screen and documented as having
a bullous skin condition (‘scalded-skin syndrome’). However, given
the very young age at referral (,1 year), and since the deletion was
inherited from a father with learning difficulties, it is possible that a
neurodevelopmental disorder will later manifest also in this
patient.
We were able to investigate the inheritance pattern of the
variations within the family trio (father, mother and affected child)
for twenty-six of the carrier patients. One duplication (male
proband) and four deletions (three males and one female) arose de
novo, whereas twenty-one variations were inherited from a parent,
including fourteen duplications (six maternal and eight paternal)
and seven deletions (five maternal and two paternal).
We identified two patients carrying identical non-NAHR
mediated microdeletions of NTAN1; both the variations arose de
novo and have been identified in a ten years old male referred for
autism spectrum disorder (ASD) and learning difficulties, and in a
five years old male referred for attention difficulties, delayed
speech and language skills and dysmorphic features. The deletions
involve a 23 kbp genomic interval (chr16:15,131,723–15,154,746)
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and encompass the entire NTAN1 gene, one of the strongest
candidate genes in the 16p13.11 region (Figure S1). NTAN1
encodes the asparagine-specific N-terminal amidase, an enzyme
involved in the regulation of the in vivo half life of proteins;
inactivation of the NTAN1 gene in mice has been associated with
abnormal neurological features such as altered social behaviour
and impaired spatial and non-spatial learning and memory [43–
45]. Interestingly, whilst the patient referred for attention
difficulties, speech delay and dysmorphic features also harboured
a maternally inherited, putatively pathogenic duplication, affecting
part of the IL1RAPL1 gene (Xp21.2), the patient with a specific
diagnosis of ASD and learning difficulties did not carry any
additional genomic imbalance, which could suggest the involve-
ment of the NTAN1 gene in the aetiology of the neurodevelop-
mental disorder.
Patients with NAHR-mediated duplications, the larger group
identified, presented with a wide range of abnormal phenotypes.
Consistent with the ascertainment criteria, we observed develop-
mental delay (DD) (12/24) and dysmorphic features (n = 11) in
most cases; importantly, the majority of patients older than 2 years
(14/18) presented with a specific neurologic/neuropsychiatric
phenotype, including autism spectrum disorder (ASD) (n = 4),
speech and language delay (n = 5), learning difficulties (n = 3),
behavioural problems (n = 2), microcephaly (n = 2), epileptic
seizure (n = 1) and attention deficit hyperactivity disorder (ADHD)
(n = 1). Other relevant clinical features included cardiac anomalies
(n = 2), motor delay (n = 1) and obesity (n = 1) (Table 4, Table S1).
We also identified a mildly affected carrier mother with speech
delay. There were no notable phenotypic differences among
carriers of duplications with different size. Additional genomic
imbalances were identified in six of the 28 probands, including a
male patient referred for ASD, harbouring an additional
maternally inherited duplication at 6q21, a region with reported
linkage to schizophrenia and bipolar disorder [46,47], a female
patient diagnosed with DD and microcephaly carrying an
additional duplication at 22q11.22q11.23, recently associated with
DD, hyperactivity, and epilepsy [48], and a proband harbouring
an additional paternally inherited deletion of uncertain signifi-
cance at 6p22.2. The other three duplication carriers with an
additional genomic imbalance included a male patient referred for
DD and physical dysmorphisms, harbouring an additional
duplication at 7q11.23, the Williams-Beuren Syndrome critical
region, recently associated with autism [49], a female patient
referred for DD, microcephaly and physical dysmorphisms
presenting with a complex chromosome 7 rearrangement, and a
male patient diagnosed with ASD or Asperger syndrome carrying
a duplication of uncertain significance at Xp22.33, flanking the
SHOX gene.
The majority of patients with NAHR-mediated deletions
presented with developmental delay (8/14); importantly, all
patients older than 2 years (8/8) manifested a specific neurolog-
ic/neuropsychiatric phenotype, including learning difficulties
(n = 6), speech and language delay (n = 3), behavioural problems
(n = 3), microcephaly (n = 3), autism spectrum disorder (n = 2) and
epilepsy (n = 2). Other relevant abnormal phenotypes included
dysmorphic features (n = 5), motor delay (n = 3) and cardiac
anomalies (n = 1) (Table 4, Table S1). We also identified a carrier
father mildly affected with learning difficulties. There were no
notable phenotypic differences among carriers of deletions with
different size. Additional genomic imbalances were identified in
five of the 16 probands, including a male patient referred for
motor delay, harbouring an additional maternally inherited
deletion at 17q23.3, encompassing the Silver-Russell syndrome
candidate gene CSH1, a male patient diagnosed with DD and
microcephaly carrying an additional deletion at 7q11.22, involving
the entire autism susceptibility candidate 2 (AUTS2) gene, a
Figure 1. NAHR-mediated duplications and deletions of 16p13.11. NAHR-mediated duplications (blue) and deletions (red) identified in the
16p13.11–p12.3 region (Chr16:14.66–18.70 Mb, GRCh37/hg19) in cases and controls; case and control IDs refer to Table S1 and Table S2. Black solid
bars indicate the three single copy sequence intervals in the region. Red and blue gene symbols represent ohnologs and other genes respectively.
Segmental duplications and low copy repeats (LCRs) in the region are also shown.
doi:10.1371/journal.pone.0061365.g001
Table 1. NAHR-mediated duplications and deletions of 16p13.11 identified in the BB-GRE referral cases.
Total Sample Male only Female only
CNV Cases (N=10,397)* Controls (N=10,375) Cases (N=6,595) Controls (N=4,474) Cases (N=3,802) Controls (N=5,901)
All Dupl 28 13 20 4 7 9
All Del 16 4 13 0 3 4
Dupl I 0 0 0 0 0 0
Dupl I+II 16 8 11 3 5 5
Dupl I+II+III 1 1 0 0 0 1
Dupl II 1 0 1 0 0 0
Dupl II+III 10 4 8 1 2 3
Del I 0 0 0 0 0 0
Del I+II 9 4 7 0 2 4
Del I+II+III 1 0 1 0 0 0
Del II 0 0 0 0 0 0
Del II+III 6 0 5 0 1 0
Abbreviations: Dupl, duplication; Del, deletion.
*The sex of one of the cases carrying a duplication of intervals I, II and III was unknown, consequently, we were unable to include him/her in the male or female
subgroup.
doi:10.1371/journal.pone.0061365.t001
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female patient referred for ASD, motor delay, microcephaly and
physical dysmorphisms harbouring a maternally inherited deletion
of uncertain significance at 17q21.32, encompassing part of the
C17orf57 gene, and a male patient diagnosed with DD, motor
delay and speech delay carrying a duplication of uncertain
significance at 4q13.3. The other deletion carrier presenting with
an additional genomic imbalance was the male proband referred
for scalded-skin syndrome, who harboured an additional mater-
nally inherited deletion at 13q12.12, encompassing the
TNFRSF19 gene, in a region with reported linkage to epilepsy
[50] (Table S1).
16p13.11 CNVs in DECIPHER
Performing a search in the DECIPHER database (https://
decipher.sanger.ac.uk) [41], we identified 101 subjects with
NAHR-mediated CNVs at the 16p13.11 locus, including 61
duplications and 40 deletions (Figure S2, Table S4). Phenotypic
information was available for 78 of the 101 patients (49
duplication carriers and 29 deletion carriers), and between them,
seven cases (patients 250947, 250061, 1230, 249225, 993, 4598,
250436) were not diagnosed with a neurodevelopmental disorder,
but were referred for physical dysmorphism and congenital
anomalies. Information about the inheritance pattern of the
variations was available for seventy-one family trios. Five
duplications (3 males, 1 female, and 1 unknown sex) and seven
deletions (6 males and 1 female) arose de novo, whereas fifty-nine
variations were inherited from a parent, including forty duplica-
tions (24 maternal, 11 paternal, and 5 unknown sex) and nineteen
deletions (8 paternal, 6 maternal, and 5 unknown sex). Twenty-
seven of the 101 patients (19 duplication carriers and 8 deletion
carriers) harboured one or more additional genomic imbalances,
either clinically significant (37%) or of uncertain clinical
significance (63%) (Table S4).
Notably, the DECIPHER database search also identified two
patients (250140 and 265264) carrying non-NAHR mediated
23 kbp microdeletions encompassing the NTAN1 gene
(chr16:15,131,723–15,154,746) identical to those we found in
two cases of the referral series (Figure S1). Phenotypes of the
patients and inheritance pattern of the variations were unknown,
and both probands harboured a second genomic imbalance of
uncertain significance (dupl 2q13 and del 12q13.3) (Table S4).
Patients with duplications mostly presented with developmental
delay (43/49) and physical dysmorphism (n = 24). In line with our
clinical referral cases, the majority of patients older than 2 years
(29/35) were also diagnosed with a neurologic/neuropsychiatric
phenotype, including speech and language delay (n = 20), learning
difficulties (n = 19), autism spectrum disorder (n = 6), behavioural
problems (n = 6), ADHD (n = 5), microcephaly (n = 4) and seizures
(n = 3). Other important phenotypic features observed in more
than one duplication carrier included motor delay (n = 14),
congenital anomalies (n = 14) and obesity (n = 6) (Table 4).
Seventeen carrier parents (9 mothers, 7 fathers, and 1 unknown
sex) were also mildly affected with developmental delay and speech
delay, while one carrier mother was severely affected with speech
delay and learning difficulties. Twenty-two parents (14 mothers, 4
fathers, and 4 unknown sex) harbouring the duplications were
apparently unaffected (Table S4).
The majority of patients with deletions presented with
developmental delay (25/29); neurologic/neuropsychiatric pheno-
types observed in patients older than 2 years (15/20) included
speech and language delay (n = 8), seizures (n = 7), learning
difficulties (n = 5), microcephaly (n = 5), autism (n = 3), macro-
cephaly (n = 2) and behavioural problems (n = 1). Other relevant
abnormal phenotypes included physical dysmorphism (n = 12),
congenital anomalies (n = 12) and motor delay (n = 9) (Table 4).
Seven carrier parents (3 mothers and 4 fathers) were also mildly
affected with developmental delay and speech delay, while twelve
parents (3 mothers, 4 fathers, and 5 unknown sex) with the same
deletions were apparently unaffected (Table S4).
Discussion
In the present study, we report evidence for a male-biased
autosomal effect of 16p13.11 duplications and deletions in a
sample of 10,397 individuals with a neurodevelopmental condi-
tion, analysed by whole-genome array comparative genomic
hybridisation (aCGH). The CNVs identified included 28 duplica-
tions with size ranging from 0.8 Mb to 3.29 Mb and 18 deletions
with size between 0.02 Mb and 3.26 Mb (2 non-NAHR mediat-
ed), each encompassing one or more of the three genomic intervals
(I, II and III) previously identified at this locus [19]. The male-
biased prevalence of the 16p13.11 variations was also confirmed in
the DECIPHER sample, where we identified 101 patients with
NAHR-mediated CNVs at the 16p13.11 locus, including 61
duplications and 40 deletions.
Both duplications and deletions were associated with a wide
range of phenotypic manifestations. Consistent with the ascertain-
ment criteria, the most common phenotypes observed were
Table 2. Frequency of NAHR-mediated 16p13.11 duplications
and deletions in BB-GRE cases and controls.
16p13.11 CNV Cases (%) Controls (%) OR (95% CI) p-value
All 44 (0.42) 17 (0.16) 2.59 (1.48–4.53) 0.0005
Duplications 28 (0.27) 13 (0.12) 2.15 (1.11–4.16) 0.019
Deletions 16 (0.15) 4 (0.04) 4.00 (1.34–11.96) 0.007
Abbreviations: CNV, copy number variant; OR, odds ratio; CI, confidence
interval.
doi:10.1371/journal.pone.0061365.t002
Table 3. Ohnologs in the 16p13.11–p12.3 region.
Ensembl id Gene symbol Full name
ENSG00000072864 NDE1 NudE nuclear distribution gene E homolog 1
ENSG00000133392 MYH11 Myosin heavy chain 11
ENSG00000103222 ABCC1 ATP-binding cassette, sub-family C, member 1
ENSG00000091262 ABCC6 ATP-binding cassette, sub-family C, member 6
ENSG00000103489 XYLT1 Xylosyltransferase 1
doi:10.1371/journal.pone.0061365.t003
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developmental delay/learning disability and physical dysmor-
phism, however, the majority of patients older than 2 years also
presented with a specific neurologic/neuropsychiatric phenotype,
including autism spectrum disorders, speech and language delay,
seizures, behavioural problems, microcephaly and attention deficit
hyperactivity disorder. Notably, in line with previous reports,
seizures were most commonly observed among deletion carriers
(32.1% vs 7.5%) [20–22], while ADHD was only present in
duplication carriers (11.3%) [23].
Information about the inheritance pattern of the variations was
available for twenty-six families of our clinical referral series and
seventy-one DECIPHER families; overall, 17.5% of the probands
harboured a de novo event, while 82.5% inherited the variation
from a carrier parent. Interestingly, we observed an enrichment of
de novo duplications and deletions in affected males (13 de novo
events in affected males vs 3 de novo events in affected females, p
value = 0.0004), consistent with purifying selection and thus higher
penetrance of the variations in the male gender. Phenotypic
information was available for sixty-one carrier parents; of them,
one mother harbouring a duplication, was severely affected with
developmental delay, speech delay and learning difficulties, while
the remaining carrier parents were only mildly affected (n = 26), or
completely unaffected (n = 34). The present data thus suggest that
duplications and deletions at chromosome 16p13.11 represent
pathogenic variants with incomplete penetrance, a pattern
frequently observed for CNVs associated with complex genetic
disorders [51]. Notably, we also observed a trend toward a parent-
of-origin effect, with carrier mothers being more likely than fathers
to transmit a CNV to an affected proband (31 carrier mothers vs
20 carrier fathers, p value = 0.029).
Twelve patients of the referral series (26.1%) and twenty-seven
DECIPHER patients (26.7%) also harboured a second genomic
imbalance that was either clinically significant or of uncertain
clinical significance. These additional CNVs might act in concert
in a ‘‘two-hit’’ model with the 16p13.11 variants to increase
penetrance or severity; notably, the ‘‘double-hit’’ model was first
proposed for patients with deletions at 16p12.1, a region located in
close proximity to the 16p13.11 locus, and the frequency of cases
with a second-hit CNV in the present study is very similar to that
observed in the original report [40].
Association analysis showed a significant enrichment of NAHR-
mediated CNVs in the cases compared with controls, with the
strongest overrepresentation coming from deletions. In line with
our preliminary hypothesis, we observed a sex-biased effect, with a
significant enrichment of CNVs only in the male subgroup of
cases, also confirmed in the DECIPHER sample. All the findings
also held after excluding from the analysis cases and controls with
rare second-hit CNVs .500 kpb in size. Assuming an equal
incidence of the 16p13.11 imbalances in males and females, our
data clearly suggest a male bias in the penetrance of the
neurodevelopmental phenotypes at the 16p13.11 locus. Impor-
tantly, in re-examining the data reported in the literature, we
found a trend toward a male-specific prevalence of 16p13.11
duplications also in schizophrenia-affected patients [19], which
provides further support for our findings.
A male biased sex ratio is typical of several neurodevelopmental
disorders including attention deficit hyperactivity disorder, Tour-
ette syndrome, dyslexia, language delay and, particularly, autism
and Asperger syndrome [52]. The specific factors responsible for
the higher male prevalence remain unclear; however, prenatal
androgens and, in particular, the exposure to high maternal
intrauterine testosterone levels, are thought to play a key role,
being putatively responsible for the unusually hypermasculinized
traits observed in individuals affected by different male-based
neurodevelopmental disorders, such as autism or ADHD
[26,52,53]. Genetic factors are also likely to be determinant, and
recent studies suggest that stronger genetic perturbations are
required to trigger an autistic phenotype in females than males,
including CNVs encompassing a larger number of genes or CNVs
affecting genes that produce a more deleterious impact when
disrupted [54,55]; the specific compensatory mechanisms behind
this greater resistance in females are currently unknown, although
the well-established sexual differences in cognition, neuroanatomy
and neural function observed in males and females across
development, are likely to play an important role [26]. A
decreased or impaired interhemispheric connectivity, for example,
has been associated with different neurodevelompmental disor-
ders, including autism and schizophrenia [56,57], and interesting-
ly, despite smaller brain size in females than in males, females
generally show larger corpora callosa and increased interhemi-
spheric connectivity compared to males [26], which might reflect a
Table 4. Frequency of phenotypic features in individuals with 16p13.11 duplications and deletions.
Phenotypes Duplications Deletions
BB-GRE Decipher Overall % BB-GRE Decipher Overall %
Developmental delay 12/24 43/49 55/73 75.3% 8/14 25/29 33/43 76.7%
Dysmorphic features 11/24 24/49 35/73 47.9% 5/14 12/29 17/43 39.5%
Speech delay* 5/18 20/37 25/55 45.4% 3/8 8/20 11/28 39.3%
Learning difficulties* 3/18 19/35 22/53 41.5% 6/8 5/19 11/27 40.7%
Psychiatric/Behavioural problems 6* 7/18 17/35 24/53 45.3% 5/8 4/19 9/27 33.3%
Seizures* 1/18 3/35 4/53 7.5% 2/8 7/20 9/28 32.1%
Microcephaly* 2/18 4/35 6/53 11.3% 3/8 5/20 8/28 28.6%
Congenital anomalies 4/24 14/49 18/73 24.7% 2/14 12/29 14/43 32.6%
Motor delay* 1/18 14/35 15/53 28.3% 3/8 9/21 12/29 41.4%
Obesity* 1/18 6/35 7/53 13.2% - 1/20 1/28 3.6%
6 This phenotype includes the diagnosis of behavioural problems, ADHD and autism spectrum disorder.
ADHD was present only in duplication carriers (11.3%), but not in deletion carriers.
*Not evaluated in very young cases.
doi:10.1371/journal.pone.0061365.t004
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higher robustness that offers females protection. Furthermore,
another major determinant of the higher threshold of liability
observed in females could be represented by dynamic factors that
operate above and beyond the generally stable DNA sequence
variations, such as sex-specific differences in gene regulation or
sexually dimorphic epigenetic processes. Intriguingly, recent
findings suggest that the amygdala, a major component of the
‘‘social brain’’, exhibits sex differences on multiple epigenetic
factors during brain development, and specifically, in neonatal
males the amygdala shows a decreased expression of both enzymes
involved in DNA methylation and factors essential for reading the
methylation marks that alter gene expression; this novel observa-
tion is thought to reflect an increased window of differentiation for
the male amygdala, which could in turn put males at higher risk
for developing altered social behaviour and mental health
problems later in life, if any perturbation occurs during this
extended period of neuronal differentiation [29].
Performing a search for the disease-causing genes in the 16p13.11
region, we observed a significant enrichment of case duplications and
deletions containing interval II, which is located between 15.49
and 16.32 Mb and encompasses a core set of nine genes
(MPV17L.ABCC6). This particular interval has shown to be
exquisitely dosage-sensitive, because pathogenic when either dupli-
cated or deleted and is thus likely to represent the core pathogenic
region at the 16p13.11 locus, harbouring the dosage-sensitive genes
responsible for the deleterious phenotypes observed in our cases.
Finally, we also applied an evolutionary genetic approach and tested
for the presence of ohnologs in the 16p13.11 region.
Vertebrate evolution has been characterized by two whole
genome duplication (WGD) events; many of the duplicated copies
(‘‘ohnologs’’) have been lost during the evolution, but some of them
have been retained in the vertebrate genome. Over 60% of retained
ohnologs seem to be refractory to small-scale duplication (SSD) and
copy number variation (CNV) in human populations and are
significantly enriched in human disease genes, consequently, they
are thought to represent ancient dosage-balanced genes (dosage-
balanced ohnologs, DBOs), resistant to copy number change
because it leads to deleterious phenotypes under negative genetic
selection [42,58]; ohnologs at the 16p13.11 locus, therefore, may be
more likely than other genes to play an important role in the
aetiology of the pathological phenotypes associated with the
16p13.11 copy number variants. Consistent with this hypothesis
we found that four of the five ohnologs identified at 16p13.11
(NDE1, MYH11, ABCC1 and ABCC6) were contained in the core
pathogenic region significantly overrepresented in our case CNVs,
and we therefore suggest that they represent important candidates
for the observed deleterious phenotypes.
The MYH11 gene encodes the smooth muscle cell (SMC)-
specific isoform of b-myosin heavy chain, a major specific
contractile protein produced in SMC, and represents the most
important candidate gene in the 16p13.11 region for the
predisposition to thoracic aortic aneurysm and dissection (TAAD)
[25]; heterozygous mutations in the MYH11 gene have been
identified in individuals with familial TAAD and are thought to be
able to disrupt SMC contractile function, leading to an early and
severe decrease in the elasticity of the aortic wall [59].
ABCC1 and ABCC6 encode the multidrug resistance-associated
proteins 1 and 6, two members of the ATP-binding cassette (ABC)
transporters superfamily [60]. These two genes have not so far been
associated with neurodevelopmental conditions; however, muta-
tions in ABCC6 are responsible for pseudoxanthoma elasticum
(OMIM 264800), a multisystem genetic disorder characterised by
dystrophic mineralisation of soft connective tissues in a number of
organs, including skin, eyes and arterial blood vessels [61].
Finally, the NDE1 gene represents the strongest candidate for
the neurodevelopmental phenotypes associated with the
16p13.11 CNVs. It encodes the nuclear distribution protein nudE
homolog 1, a centrosomal protein which plays a crucial role in the
process of mammalian encephalisation and human cerebral cortex
growth, because of its involvement in mitosis, neuronal migration
and microtubule organization during brain development [62].
Loss of NDE1 in mouse models causes profound defects in
cerebral corticogenesis and neuronal proliferation and migration,
and mutations in NDE1 have been associated with extreme
microlissencephaly in humans [63,64]. NDE1 and its homolog
NDEL1 (Nuclear distribution protein nudE-like 1) physically
interact with LIS1 (Lissencephaly 1), the first lissencephaly gene
identified, and form a complex involved in neuronal proliferation,
differentiation, and migration within the brain [65]. Importantly,
the NDE1/LIS1/NDEL1 complex is part of the disrupted in
schizophrenia-1 (DISC1) pathway, one of the most relevant
pathways underlying psychosis, and directly binds the DISC1
gene; furthermore, NDE1 subcellular localization and protein-
protein interactions are modulated through phosphorylation by
the cAMP-activated protein kinase A (PKA), and DISC1 is able to
modulate the PKA phosphorilation of NDE1 via regulation of the
activity of PDE4, a cAMP-hydrolyzing enzyme which creates a co-
complex with DISC1 and NDE1/LIS1/NDEL1 [66,67].
Interestingly, several studies have reported evidence of sex-
specific associations of sequence variations in the DISC1 gene and
a number of neuropsychiatric disorders, including schizophrenia,
bipolar disorder, major depression, autism and Asperger syn-
drome, as well as with a variety of neurocognitive endophenotypes
[68–73]. The most robust association has been observed for a two-
marker haplotype (HEP3) spanning a 62 kbp genomic region from
intron 1 to exon 2 of the DISC1 gene, which was originally found
to confer significant risk of schizophrenia only to male probands in
a sample of Finnish families [68], and has subsequently been
associated to the neurocognitive measure of visual working
memory only in males [69]. Notably, a later study in the same
sample of Finnish families also found sex-dependent evidence of
association between a tag-haplotype in the NDE1 gene and risk of
schizophrenia only in females [74].
Further support for a possible sex-specific effect of the DISC1
pathway in conferring risk for mental illness, also comes from
animal studies. Using a new transgenic mouse model, Pletnikov
et al. found that the expression of a mutant human truncated
DISC1 protein (hDISC1) in forebrain areas of the mouse brain
produces sex-dependent behavioural effects, with male mice
showing increased spontaneous locomotor activity and attenuated
social behaviour and female mice exhibiting impaired spatial
memory and depression-like behaviour [75,76]. These evidences
suggest the possible involvement of the NDE1 gene and, more
generally, of the DISC1 risk pathway, in the sex-biased effect
observed for the 16p13.11 copy number variants, however,
additional studies will be needed to explore the possible molecular
mechanisms mediating such an effect.
Recently, the specific role of NDE1 as disease-causing candidate
gene at 16p13.11 has been investigated in a preliminary study by
Liu et al. [77], examining surgically resected brain tissues from
two patients with mesial temporal lobe epilepsy (MTLE), carrying
identical heterozygous 16p13.11 deletions encompassing the
NDE1 gene. The authors did not find any detectable structure
alteration in the brain tissues with the methods employed, which
might suggest that, at least in the two cases examined, the deletion
of NDE1 could not represent the key contributor to the patients
phenotype, or that it could act at a different level than the one
examined in the study [77]; despite the very small clinical sample,
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the study highlights the importance of deep phenotyping analysis
for the interpretation of the present genetic findings, outlining a
crucial direction for future work.
There are potential limitations in the case-control analysis
performed in the present study, which arise because of the
different CNV detection methods used for the generation of the
data in cases (Agilent CGH array) and controls (Illumina SNP
genotyping arrays). Platform heterogeneity in CNV detection may
produce false CNV enrichment signals, as a function of different
probe density and distribution (gene-centric probes on array
CGH, especially focussed on known disease variants), different
analysis methods, etc. This means that not all regions of the
genome will be directly comparable, and some CNV identified by
array CGH may be missed by Illumina genotyping arrays and
vice-versa. Platform heterogeneity, however, is unlikely to
represent a major confounding factor in the present study, as
platform-specific differences in sensitivity and specificity have been
found to largely disappear for large CNVs (.500 kbp in size) [37–
40], and the 16p13.11 locus is a known CNV region harbouring
NAHR-mediated variations with size.800 kbp, and is adequately
covered by both our array CGH probes and Illumina genotyping
array probes for the detection of such events.
In summary, we studied the impact of duplications and
deletions at chromosome 16p13.11 in a clinical sample of children
and young adults with a range of neurodevelopmental disorders,
analysed by array comparative genomic hybridisation (aCGH).
While phenotype-led studies have recently implicated these
genomic variations in different specific syndromes [15–25], we
used a CNV-led approach aiming to capture the full range of
phenotypic diversity associated with these pleiotropic variants
[12]. The male-biased effect observed in the present study for the
16p13.11 genomic imbalances is intriguing, in that it could help to
shed some light on the complex genetic and biological mechanisms
underlying the yet poorly understood male bias characteristic of a
number of neurodevelopmental disorders. Nearly all human
diseases exhibit sexually dimorphic features in prevalence, course
and severity; uncovering the bases of such differences could offer
unprecedented insights into the aetiology of complex disorders and
thus provide concrete means for the design of effective interven-
tion and treatment.
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Figure S1 Microdeletions of NTAN1. Microdeletions at
[chr16:15,131,723–15,154,746] identified in two cases of the
referral series (Case 1 and Case 2) and in two cases reported in the
DECIPHER database (patients 250140 and 265264) (http://
genome.ucsc.edu/).
(TIF)
Figure S2 NAHR-mediated duplications and deletions
of 16p13.11 in the DECIPHER cases. NAHR-mediated
duplications (blue) and deletions (red) identified in the 16p13.11-
p12.3 region (Chr16:14.66–18.70 Mb, GRCh37/hg19) in the
DECIPHER referral cases. Segmental duplications in the region
are also shown (http://genome.ucsc.edu/).
(TIF)
Table S1 Genotype–phenotype correlation for patients
with duplication or deletion of 16p13.11 identified in the
clinical referral series.
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tified in the control cohorts.
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(PDF)
Acknowledgments
We would like to thank Prof Evan Eichler, Dr Bradley Coe and the CHOP
CNV team for the kind cooperation and for sharing the gender data for
controls. We thank Dr Aoife McLysaght and Dr Takashi Makino for
providing the ohnologs data. We also thank Drs J. Swaminathan, E.
Bijlsma, B. Dallapiccola, A. Destre´e, H. Goel, J. Graakjaer, S. Kjærgaard,
C. Le Caignec, F. Mari, M. Mucciolo, A. Novelli, A. Renieri, C.
Rosenberg, J. Shelagh, M. Splitt, Z. Tu¨mer and O. Vanakker for providing
additional data on the DECIPHER families. This study makes use of data
generated by the DECIPHER Consortium. A full list of centres who
contributed to the generation of the DECIPHER data is available from
http://decipher.sanger.ac.uk and via email from ; decipher@sanger.ac.uk.
Those who carried out the original analysis and collection of the
DECIPHER data bear no responsibility for the further analysis or
interpretation.
Author Contributions
Conceived and designed the experiments: MT JWA RJBD CMO SC
DAC. Performed the experiments: MT JWA GB JR CMO SC DAC.
Analyzed the data: MT JWA EV CMO DAC. Contributed reagents/
materials/analysis tools: AD DKP PM AF PSW JA. Wrote the paper: MT.
References
1. Feuk L, Carson AR, Scherer SW (2006) Structural variation in the human
genome. Nat Rev Genet 7: 85–97.
2. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, et al. (2004)
Detection of large-scale variation in the human genome. Nat Genet 36: 949–
951.
3. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, et al. (2004) Large-scale copy
number polymorphism in the human genome. Science 305: 525–528.
4. Freeman JL, Perry GH, Feuk L, Redon R, McCarroll SA, et al. (2006) Copy
number variation: new insights in genome diversity. Genome Res 16: 949–961.
5. International Schizophrenia Consortium (2008) Rare chromosomal deletions
and duplications increase risk of schizophrenia. Nature 455: 237–241.
6. Stefansson H, Rujescu D, Cichon S, Pietila¨inen OP, Ingason A, et al. (2008)
Large recurrent microdeletions associated with schizophrenia. Nature 455: 232–
236.
7. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, et al. (2007) Strong
association of de novo copy number mutations with autism. Science 316: 445–
449.
8. Vaags AK, Lionel AC, Sato D, Goodenberger M, Stein QP, et al. (2012) Rare
deletions at the neurexin 3 locus in autism spectrum disorder. Am J Hum Genet
90: 133–141.
9. Whiteley P, Todd L, Carr K, Shattock P (2010) Gender Ratios in Autism,
Asperger Syndrome and Autism Spectrum Disorder. Autism Insights 2: 17–24.
10. McGrath J, Saha S, Chant D, Welham J (2008) Schizophrenia: a concise
overview of incidence, prevalence, and mortality. Epidemiol Rev 30: 67–76.
11. Constantino JN, Charman T (2012) Gender bias, female resilience, and the sex
ratio in autism. J Am Acad Child Adolesc Psychiatry 51: 756–758.
12. O’Donovan MC, Kirov G, Owen MJ (2008) Phenotypic variations on the theme
of CNVs. Nat Genet 40: 1392–1393.
13. Martin J, Han C, Gordon LA, Terry A, Prabhakar S, et al. (2004) The sequence
and analysis of duplication-rich human chromosome 16. Nature 432: 988–994.
14. Inoue K, Lupski JR (2002) Molecular mechanisms for genomic disorders. Annu
Rev Genomics Hum Genet 3: 199–242.
Male-Biased Effect of 16p13.11 CNVs
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e61365
15. Ullmann R, Turner G, Kirchhoff M, Chen W, Tonge B, et al. (2007) Array
CGH identifies reciprocal 16p13.1 duplications and deletions that predispose to
autism and/or mental retardation. Hum Mutat 28: 674–682.
16. Hannes FD, Sharp AJ, Mefford HC, de Ravel T, Ruivenkamp CA, et al. (2009)
Recurrent reciprocal deletions and duplications of 16p13.11: the deletion is a
risk factor for MR/MCA while the duplication may be a rare benign variant.
J Med Genet 46: 223–232.
17. Kirov G, Grozeva D, Norton N, Ivanov D, Mantripragada KK, et al. (2009)
Support for the involvement of large copy number variants in the pathogenesis
of schizophrenia. Hum Mol Genet 18: 1497–1503.
18. Ikeda M, Aleksic B, Kirov G, Kinoshita Y, Yamanouchi Y, et al. (2010) Copy
number variation in schizophrenia in the Japanese population. Biol Psychiatry
67: 283–286.
19. Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, et al. (2011)
Copy number variations of chromosome 16p13.1 region associated with
schizophrenia. Mol Psychiatry 16: 17–25.
20. Mefford HC, Muhle H, Ostertag P, von Spiczak S, Buysse K, et al. (2010)
Genome-wide copy number variation in epilepsy: novel susceptibility loci in
idiopathic generalized and focal epilepsies. PLoS Genet 6: e1000962.
21. Heinzen EL, Radtke RA, Urban TJ, Cavalleri GL, Depondt C, et al. (2010)
Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy
syndromes. Am J Hum Genet 86: 707–718.
22. de Kovel CG, Trucks H, Helbig I, Mefford HC, Baker C, et al. (2010) Recurrent
microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized
epilepsies. Brain 133: 23–32.
23. Williams NM, Zaharieva I, Martin A, Langley K, Mantripragada K, et al. (2010)
Rare chromosomal deletions and duplications in attention-deficit hyperactivity
disorder: a genome-wide analysis. Lancet 376: 1401–1408.
24. Nagamani SC, Erez A, Bader P, Lalani SR, Scott DA, et al. (2011) Phenotypic
manifestations of copy number variation in chromosome 16p13.11. Eur J Hum
Genet 19: 280–286.
25. Kuang SQ, Guo DC, Prakash SK, McDonald ML, Johnson RJ, et al. (2011)
Recurrent chromosome 16p13.1 duplications are a risk factor for aortic
dissections. PLoS Genet 7: e1002118.
26. Baron-Cohen S, Knickmeyer RC, Belmonte MK (2005) Sex differences in the
brain: implications for explaining autism. Science 310: 819–823.
27. Ober C, Loisel DA, Gilad Y (2008) Sex-specific genetic architecture of human
disease. Nat Rev Genet 9: 911–922.
28. Weiss LA, Pan L, Abney M, Ober C (2006) The sex-specific genetic architecture
of quantitative traits in humans. Nat Genet 38: 218–222.
29. Jessen HM, Auger AP (2011) Sex differences in epigenetic mechanisms may
underlie risk and resilience for mental health disorders. Epigenetics 6: 857–861.
30. Ahn JW, Mann K, Walsh S, Shehab M, Hoang S, et al. (2010) Validation and
implementation of array comparative genomic hybridisation as a first line test in
place of postnatal karyotyping for genome imbalance. Mol Cytogenet 3: 9.
31. Hills A, Ahn JW, Donaghue C, Thomas H, Mann K, et al. (2010) MLPA for
confirmation of array CGH results and determination of inheritance. Mol
Cytogenet 3: 19.
32. McGuffin P, Katz R, Aldrich J (1986) Past and present state examination: the
assessment of ’lifetime ever’ psychopathology. Psychol Med 16: 461–465.
33. Beck AT, Steer RA (1984) Internal consistencies of the original and revised Beck
Depression Inventory. J Clin Psychol 40: 1365–1367.
34. Rucker JJ, Breen G, Pinto D, Pedroso I, Lewis CM, et al. (2011) Genome-wide
association analysis of copy number variation in recurrent depressive disorder.
Mol Psychiatry doi: 10.1038/mp.2011.144.
35. Shaikh TH, Gai X, Perin JC, Glessner JT, Xie H, et al. (2009) High-resolution
mapping and analysis of copy number variations in the human genome: a data
resource for clinical and research applications. Genome Res 19: 1682–1690.
36. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, et al. (2011) A copy
number variation morbidity map of developmental delay. Nat Genet 43: 838–
846.
37. Itsara A, Cooper GM, Baker C, Girirajan S, Li J, et al. (2009) Population
analysis of large copy number variants and hotspots of human genetic disease.
Am J Hum Genet 84: 148–161.
38. McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, et al. (2008)
Integrated detection and population-genetic analysis of SNPs and copy number
variation. Nat Genet 40: 1166–1174.
39. Curtis C, Lynch AG, Dunning MJ, Spiteri I, Marioni JC, et al. (2009) The
pitfalls of platform comparison: DNA copy number array technologies assessed.
BMC Genomics 10: 588.
40. Girirajan S, Rosenfeld JA, Cooper GM, Antonacci F, Siswara P, et al. (2010) A
recurrent 16p12.1 microdeletion supports a two-hit model for severe
developmental delay. Nat Genet 42: 203–209.
41. Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, et al. (2009)
DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans
Using Ensembl Resources. Am J Hum Genet 84: 524–533.
42. Makino T, McLysaght A (2010) Ohnologs in the human genome are dosage
balanced and frequently associated with disease. Proc Natl Acad Sci U S A 107:
9270–9274.
43. Kwon YT, Balogh SA, Davydov IV, Kashina AS, Yoon JK, et al. (2000) Altered
activity, social behavior, and spatial memory in mice lacking the NTAN1p
amidase and the asparagine branch of the N-end rule pathway. Mol Cell Biol 20:
4135–4148.
44. Balogh SA, Kwon YT, Denenberg VH (2000) Varying intertrial interval reveals
temporally defined memory deficits and enhancements in NTAN1-deficient
mice. Learn Mem 7: 279–286.
45. Balogh SA, McDowell CS, Tae Kwon Y, Denenberg VH (2001) Facilitated
stimulus-response associative learning and long-term memory in mice lacking
the NTAN1 amidase of the N-end rule pathway. Brain Res 892: 336–343.
46. Cichon S, Schumacher J, Mu¨ller DJ, Hu¨rter M, Windemuth C, et al. (2001) A
genome screen for genes predisposing to bipolar affective disorder detects a new
susceptibility locus on 8q. Hum Mol Genet 10: 2933–2944.
47. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, et al. (2003) Genome
scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia.
Am J Hum Genet 73: 34–48.
48. Shimojima K, Imai K, Yamamoto T (2010) A de novo 22q11.22q11.23
interchromosomal tandem duplication in a boy with developmental delay,
hyperactivity, and epilepsy. Am J Med Genet A 152A: 2820–2826.
49. Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, et al. (2011)
Multiple recurrent de novo CNVs, including duplications of the 7q11.23
Williams syndrome region, are strongly associated with autism. Neuron 70: 863–
885.
50. EPICURE Consortium, Leu C, de Kovel CG, Zara F, Striano P, et al. (2012)
Genome-wide linkage meta-analysis identifies susceptibility loci at 2q34 and
13q31.3 for genetic generalized epilepsies. Epilepsia 53: 308–318.
51. Vassos E, Collier DA, Holden S, Patch C, Rujescu D, et al. (2010) Penetrance
for copy number variants associated with schizophrenia. Hum Mol Genet 19:
3477–3481.
52. Baron-Cohen S, Lombardo MV, Auyeung B, Ashwin E, Chakrabarti B, et al.
(2011) Why are autism spectrum conditions more prevalent in males? PLoS Biol
9: e1001081.
53. James WH (2008) Further evidence that some male-based neurodevelopmental
disorders are associated with high intrauterine testosterone concentrations. Dev
Med Child Neurol 50: 15–18.
54. Levy D, Ronemus M, Yamrom B, Lee YH, Leotta A, et al. (2011) Rare de novo
and transmitted copy-number variation in autistic spectrum disorders. Neuron
70: 886–897.
55. Gilman SR, Iossifov I, Levy D, Ronemus M, Wigler M, et al. (2011) Rare de
novo variants associated with autism implicate a large functional network of
genes involved in formation and function of synapses. Neuron 70: 898–907.
56. Anderson JS, Druzgal TJ, Froehlich A, DuBray MB, Lange N, et al. (2011)
Decreased interhemispheric functional connectivity in autism. Cereb Cortex 21:
1134–1146.
57. Kubicki M, Styner M, Bouix S, Gerig G, Markant D, et al. (2008) Reduced
interhemispheric connectivity in schizophrenia-tractography based segmentation
of the corpus callosum. Schizophr Res 106: 125–131.
58. Makino T, Hokamp K, McLysaght A (2009) The complex relationship of gene
duplication and essentiality. Trends Genet 25: 152–155.
59. Zhu L, Vranckx R, Khau Van Kien P, Lalande A, Boisset N, et al. (2006)
Mutations in myosin heavy chain 11 cause a syndrome associating thoracic
aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet 38:
343–349.
60. Keppler D (2011) Multidrug resistance proteins (MRPs, ABCCs): importance for
pathophysiology and drug therapy. Handb Exp Pharmacol 201: 299–323.
61. Bergen AA, Plomp AS, Schuurman EJ, Terry S, Breuning M, et al. (2000)
Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet 25: 228–
231.
62. Bakircioglu M, Carvalho OP, Khurshid M, Cox JJ, Tuysuz B, et al. (2011) The
essential role of centrosomal NDE1 in human cerebral cortex neurogenesis.
Am J Hum Genet 88: 523–535.
63. Feng Y, Walsh CA (2004) Mitotic spindle regulation by Nde1 controls cerebral
cortical size. Neuron 44: 279–293.
64. Alkuraya FS, Cai X, Emery C, Mochida GH, Al-Dosari MS, et al. (2011)
Human mutations in NDE1 cause extreme microcephaly with lissencephaly.
Am J Hum Genet 88: 536–547.
65. Feng Y, Walsh CA (2001) Protein-protein interactions, cytoskeletal regulation
and neuronal migration. Nat Rev Neurosci 2: 408–416.
66. Bradshaw NJ, Ogawa F, Antolin-Fontes B, Chubb JE, Carlyle BC, et al. (2008)
DISC1, PDE4B, and NDE1 at the centrosome and synapse. Biochem Biophys
Res Commun 377: 1091–1096.
67. Bradshaw NJ, Soares DC, Carlyle BC, Ogawa F, Davidson-Smith H, et al.
(2011) PKA phosphorylation of NDE1 is DISC1/PDE4 dependent and
modulates its interaction with LIS1 and NDEL1. J Neurosci 31: 9043–9054.
68. Hennah W, Varilo T, Kestila¨ M, Paunio T, Araja¨rvi R, et al. (2003) Haplotype
transmission analysis provides evidence of association for DISC1 to schizophre-
nia and suggests sex-dependent effects. Hum Mol Genet 12: 3151–3159.
69. Hennah W, Tuulio-Henriksson A, Paunio T, Ekelund J, Varilo T, et al. (2005) A
haplotype within the DISC1 gene is associated with visual memory functions in
families with a high density of schizophrenia. Mol Psychiatry 10: 1097–1103.
70. Thomson PA, Wray NR, Millar JK, Evans KL, Hellard SL, et al. (2005)
Association between the TRAX/DISC locus and both bipolar disorder and
schizophrenia in the Scottish population. Mol Psychiatry 10: 657–668.
71. Hashimoto R, Numakawa T, Ohnishi T, Kumamaru E, Yagasaki Y, et al.
(2006) Impact of the DISC1 Ser704Cys polymorphism on risk for major
depression, brain morphology and ERK signaling. Hum Mol Genet 15: 3024–
3033.
Male-Biased Effect of 16p13.11 CNVs
PLOS ONE | www.plosone.org 11 April 2013 | Volume 8 | Issue 4 | e61365
72. Palo OM, Antila M, Silander K, Hennah W, Kilpinen H, et al. (2007)
Association of distinct allelic haplotypes of DISC1 with psychotic and bipolar
spectrum disorders and with underlying cognitive impairments. Hum Mol Genet
16: 2517–2528.
73. Kilpinen H, Ylisaukko-Oja T, Hennah W, Palo OM, Varilo T, et al. (2008)
Association of DISC1 with autism and Asperger syndrome. Mol Psychiatry 13:
187–196.
74. Hennah W, Tomppo L, Hiekkalinna T, Palo OM, Kilpinen H, et al. (2007)
Families with the risk allele of DISC1 reveal a link between schizophrenia and
another component of the same molecular pathway, NDE1. Hum Mol Genet
16: 453–462.
75. Pletnikov MV, Ayhan Y, Nikolskaia O, Xu Y, Ovanesov MV, et al. (2008)
Inducible expression of mutant human DISC1 in mice is associated with brain
and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry 13:
173–186.
76. Ayhan Y, Abazyan B, Nomura J, Kim R, Ladenheim B, et al. (2011) Differential
effects of prenatal and postnatal expressions of mutant human DISC1 on
neurobehavioral phenotypes in transgenic mice: evidence for neurodevelop-
mental origin of major psychiatric disorders. Mol Psychiatry 16: 293–306.
77. Liu JY, Kasperavicˇiu¯te˙ D, Martinian L, Thom M, Sisodiya SM (2012)
Neuropathology of 16p13.11 deletion in epilepsy. PLoS One 7: e34813.
Male-Biased Effect of 16p13.11 CNVs
PLOS ONE | www.plosone.org 12 April 2013 | Volume 8 | Issue 4 | e61365
